Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $14 | $13 | $12 | $16 |
| % Growth | 8.3% | 7.8% | -24.3% | – |
| Cost of Goods Sold | $2 | $2 | $2 | $3 |
| Gross Profit | $12 | $11 | $10 | $13 |
| % Margin | 86.1% | 82.9% | 86% | 83.1% |
| R&D Expenses | $5 | $4 | $3 | $3 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $3 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $8 | $7 | $5 | $4 |
| Operating Income | $4 | $4 | $5 | $9 |
| % Margin | 28.1% | 33.2% | 44.2% | 55.7% |
| Other Income/Exp. Net | $1 | -$0 | -$1 | $0 |
| Pre-Tax Income | $5 | $4 | $5 | $9 |
| Tax Expense | $0 | $0 | $1 | $1 |
| Net Income | $4 | $4 | $4 | $8 |
| % Margin | 31.1% | 30.1% | 35.6% | 50.2% |
| EPS | 40.9 | 37.05 | 40.51 | 76.4 |
| % Growth | 10.4% | -8.5% | -47% | – |
| EPS Diluted | 38.34 | 34.77 | 38.22 | 71.97 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $5 | $5 | $5 | $10 |
| % Margin | 37.4% | 35.8% | 43.2% | 60.2% |